Medicine and Dentistry
Melanoma
100%
Immune Checkpoint Inhibitor
93%
T Cell
88%
CTLA-4
87%
Neoplasm
83%
Cytotoxic T-Cell
63%
Immune-Related Adverse Events
63%
Cancer Therapy
51%
Specific Tumor
49%
Programmed Death 1 Ligand 1
42%
Cancer Immunotherapy
35%
Tumor Progression
35%
Myasthenia gravis
30%
Immunotherapy
30%
Cell Regeneration
28%
Interleukin 2
28%
Severe Acute Respiratory Syndrome Coronavirus 2
28%
COVID-19
28%
Allogeneic Hematopoietic Stem Cell Transplantation
28%
Cyclophosphamide
28%
Antineoplastic Activity
28%
Bone Morphogenetic Protein 2
28%
Cardiac Muscle Cell
28%
Systematic Review
28%
Cardiovascular System
28%
Tumor Lysis Syndrome
28%
Mesoderm
28%
Progenitor Cell
28%
Acute Graft Versus Host Disease
28%
Biological Therapy
28%
Acute Myeloid Leukemia
28%
Atezolizumab
28%
Transient Acantholytic Dermatosis
28%
Hormone Therapy
28%
Breast Cancer
28%
Myelodysplastic Syndrome
28%
Heart Left Atrium Pressure
28%
Immunosuppressive Treatment
28%
Tumor Model
28%
Catheterization
28%
Interleukin 6 Receptor
28%
Vasculotropin Receptor 2
28%
CD8 Antigen
28%
Skin Toxicity
28%
Germ Cell
28%
Lymphocyte
28%
Tumor Vaccine
28%
Graft Versus Host Reaction
25%
Ipilimumab
24%
Infection
21%
Keyphrases
Immune Checkpoint Inhibitors
88%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
81%
Programmed Death-ligand 1 (PD-L1)
72%
Immune-related Adverse Events
70%
Melanoma
69%
T-cell Mediated
56%
Teff
51%
Tumor Growth
37%
Cancer Immunotherapy
37%
Melanocytic Tumor
37%
Anti-PD-1 Therapy
37%
Checkpoint Blockade
35%
Antitumor Activity
33%
Synergize
33%
CD8+ T Cells
33%
Checkpoint Blockade Therapy
33%
High Risk
32%
Anti-cytotoxic
31%
Tumor Immunity
31%
Myasthenia Gravis
31%
Cardiomyocytes
31%
Tumor
29%
Graft-versus-host Disease (GvHD)
28%
IL-6 Blockade
28%
Immunotherapy Toxicity
28%
Transradial Catheterization
28%
Aldesleukin
28%
NKTR-214
28%
Antiphospholipid Antibodies
28%
Tumor Lysis Syndrome
28%
Immune Checkpoint Blockade
28%
Solid Tumors
28%
Mesp1
28%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
28%
Post-transplantation Cyclophosphamide (PTCy)
28%
Kinase Insert Domain Receptor
28%
Atezolizumab
28%
Grover Disease
28%
Myelodysplastic Syndrome
28%
Acute Myeloid Leukemia
28%
Conditional Knockout
28%
Immune Suppression
28%
Systematic Literature Review
28%
Endocrine Therapy
28%
Cell Repair
28%
Mouse Heart
28%
Treatment Outcome
28%
Anti-interleukin-6 Receptor
28%
COVID-19 Pandemic
28%
Breast Cancer Patients
28%
Pharmacology, Toxicology and Pharmaceutical Science
Immune Checkpoint Inhibitor
89%
Neoplasm
77%
Malignant Neoplasm
71%
Immunotherapy
56%
Cytotoxic T Lymphocyte Antigen 4
52%
Adverse Event
41%
Melanoma
38%
Programmed Death 1 Ligand 1
37%
CD8 Antigen
36%
Solid Malignant Neoplasm
30%
Myasthenia gravis
30%
Antiphospholipid Antibody
28%
Interleukin 6 Receptor
28%
Glycoprotein Gp 100
28%
Atezolizumab
28%
Observational Study
28%
Transient Acantholytic Dermatosis
28%
Acute Myeloid Leukemia
28%
Myelodysplastic Syndrome
28%
Tumor Lysis Syndrome
28%
Cyclophosphamide
28%
Interleukin 2
28%
Acute Graft Versus Host Disease
28%
Skin Toxicity
28%
Tumor Vaccine
28%
Graft Versus Host Reaction
28%
Ipilimumab
26%
Side Effect
18%
Lung Cancer
18%
Antitumor Activity
16%
Thromboembolism
16%
Tumor Antigen
15%
Urogenital Tract Cancer
14%
Dermatological Agent
14%
Cytokine
14%
Digestive System Cancer
12%
Freund's Adjuvant
11%
Combination Therapy
11%
Metastatic Melanoma
10%
Monoclonal Antibody
9%
Programmed Cell Death
9%
Transitional Cell Carcinoma
9%
Prodrug
7%
Interleukin 2 Receptor
7%
Receptor Antibody
7%
Renal Cell Carcinoma
7%
Tumor Necrosis Factor
7%
Immunoglobulin
6%
Viral Vector
5%
CD40 Ligand
5%
